We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

QuidelOrtho

Develops, manufactures and markets rapid diagnostic tests that focus on infectious diseases, reproductive health, and... read more Featured Products: More products

Download Mobile App




Syphilis Assay Improves Lab Efficiency and Reduces Costs Through Earlier Disease Detection

By LabMedica International staff writers
Posted on 30 Aug 2024

The prevalence of syphilis and other sexually transmitted infections (STIs) in the U. More...

S. has seen a notable increase, with more than 176,000 new syphilis cases reported annually—a 36% rise in cases of primary and secondary syphilis since 2021. This surge underscores the urgent need for comprehensive and accessible diagnostic tools. In response, the Centers for Disease Control and Prevention recommends using both nontreponemal and treponemal serologic tests together to diagnose syphilis effectively. Now, a newly approved syphilis assay can provide timely and accurate diagnoses, which are vital for the effective treatment and management of the disease.

QuidelOrtho Corporation (San Diego, CA, USA) has obtained U.S. Food and Drug Administration (FDA) 510(k) clearance for its VITROS syphilis assay as part of its menu. This assay, designed for use with the automated VITROS 3600, 5600, and XT 7600 systems, qualitatively determines the presence of total antibodies (IgG and IgM) to Treponema pallidum (TP)-specific antigens in human serum and plasma. The detection of TP-specific antibodies, when evaluated alongside non-treponemal test results and clinical assessments, assists in diagnosing syphilis. The VITROS syphilis assay is not intended for blood and tissue donor screening. With this FDA clearance, the VITROS syphilis assay is now available worldwide wherever QuidelOrtho products are sold.

“As an in-demand assay for a common STI, we are pleased to offer the VITROS syphilis assay, bolstering QuidelOrtho’s infectious disease test portfolio in the U.S.,” said Bryan Hanson, Senior Vice President, President North American Commercial Operations at QuidelOrtho. “Not only does this important assay improve laboratory efficiency by allowing labs to follow the CDC’s reverse testing algorithm for syphilis screening, it also reduces costs by providing earlier disease detection, thereby reducing the need to refer tests to outside labs.”

“With an increased national incidence of syphilis and other STIs, having a quick and easy way to test in various healthcare settings is essential,” said Lily Li, Senior Director, Medical Scientific & Clinical Affairs, QuidelOrtho. “The CDC Morbidity and Mortality Weekly Report, updated in February 2024, recommends that both nontreponemal and treponemal serologic tests be used in conjunction to aid in the diagnosis of syphilis.”


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Collection and Transport System
PurSafe Plus®
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.